{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:16:43Z","timestamp":1790983003007,"version":"4.1.0"},"reference-count":64,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,4,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Imatinib mesylate has become the treatment of choice for chronic myeloid leukemia (CML): the standard dose for chronic- phase (CP) CML is 400 mg daily. Response rates are different according to Sokal score, being significantly lower in intermediate and high Sokal risk patients. Phase 1 and 2 trials have shown a dose-response effect and high-dose imatinib trials in early CP CML showed better results compared with standard dose. Our study is the first prospective trial planned to evaluate the efficacy and tolerability of high-dose imatinib in previously untreated intermediate Sokal risk CML patients. Seventy-eight patients were treated with 400 mg imatinib twice daily: complete cytogenetic response (CCgR) rates at 12 and 24 months were 88% and 91%; moreover, at 12 and 24 months 56% and 73% of CCgR patients achieved a major molecular response. The incidence of adverse events was slightly higher than reported by the most important standard-dose trials. With a median follow-up of 24 months, 3 patients progressed to advanced phase. In intermediate Sokal risk newly diagnosed CML patients, high-dose imatinib induced rapid and high response rates, apparently faster than those documented in the International Randomized Study of IFN and Imatinib for the same risk category. These clinical trials are registered at www.clinicaltrials.gov as no. NCT00510926.<\/jats:p>","DOI":"10.1182\/blood-2007-08-103499","type":"journal-article","created":{"date-parts":[[2009,2,12]],"date-time":"2009-02-12T03:04:43Z","timestamp":1234407883000},"page":"3428-3434","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":48,"title":["Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party"],"prefix":"10.1182","volume":"113","author":[{"given":"Fausto","family":"Castagnetti","sequence":"first","affiliation":[{"name":"Institute of Hematology L. & A. Ser\u00e0gnoli, University of Bologna, Bologna;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Palandri","sequence":"additional","affiliation":[{"name":"Institute of Hematology L. & A. Ser\u00e0gnoli, University of Bologna, Bologna;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilina","family":"Amabile","sequence":"additional","affiliation":[{"name":"Institute of Hematology L. & A. Ser\u00e0gnoli, University of Bologna, Bologna;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Testoni","sequence":"additional","affiliation":[{"name":"Institute of Hematology L. & A. Ser\u00e0gnoli, University of Bologna, Bologna;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Luatti","sequence":"additional","affiliation":[{"name":"Institute of Hematology L. & A. Ser\u00e0gnoli, University of Bologna, Bologna;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Soverini","sequence":"additional","affiliation":[{"name":"Institute of Hematology L. & A. Ser\u00e0gnoli, University of Bologna, Bologna;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Iacobucci","sequence":"additional","affiliation":[{"name":"Institute of Hematology L. & A. Ser\u00e0gnoli, University of Bologna, Bologna;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Breccia","sequence":"additional","affiliation":[{"name":"Department of Hematology, University La Sapienza Rome, Rome;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Rege Cambrin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, S. Luigi Gonzaga Hospital Orbassano, Torino;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Stagno","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Catania, Catania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgina","family":"Specchia","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Bari, Bari;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Galieni","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mazzoni Hospital, Ascoli Piceno;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Iuliano","sequence":"additional","affiliation":[{"name":"Hematology Unit, Giannettasio Hospital, Rossano Calabro; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Pane","sequence":"additional","affiliation":[{"name":"Centro Indagini Genetiche e Molecolari, Federico II University, Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Saglio","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, S. Luigi Gonzaga Hospital Orbassano, Torino;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Alimena","sequence":"additional","affiliation":[{"name":"Department of Hematology, University La Sapienza Rome, Rome;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Martinelli","sequence":"additional","affiliation":[{"name":"Institute of Hematology L. & A. Ser\u00e0gnoli, University of Bologna, Bologna;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Baccarani","sequence":"additional","affiliation":[{"name":"Institute of Hematology L. & A. Ser\u00e0gnoli, University of Bologna, Bologna;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianantonio","family":"Rosti","sequence":"additional","affiliation":[{"name":"Institute of Hematology L. & A. Ser\u00e0gnoli, University of Bologna, Bologna;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the GIMEMA CML Working Party","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111713111289800_B1","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia.","volume":"340","author":"Sawyers","year":"1999","journal-title":"N Engl J Med"},{"key":"2019111713111289800_B2","first-page":"1497","article-title":"A minute chromosome in human chronic granulocytic leukemia.","volume":"132","author":"Nowell","year":"1960","journal-title":"Science"},{"key":"2019111713111289800_B3","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"2019111713111289800_B4","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/315550a0","article-title":"Fused transcript of abl and bcr genes in chronic myelogenous leukaemia.","volume":"315","author":"Shtivelman","year":"1985","journal-title":"Nature"},{"key":"2019111713111289800_B5","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","article-title":"Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.","volume":"247","author":"Lugo","year":"1990","journal-title":"Science"},{"key":"2019111713111289800_B6","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR\/ABL positive cells.","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"2019111713111289800_B7","first-page":"100","article-title":"Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.","volume":"56","author":"Buchdunger","year":"1996","journal-title":"Cancer Res"},{"key":"2019111713111289800_B8","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"2019111713111289800_B9","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"2019111713111289800_B10","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N Engl J Med"},{"key":"2019111713111289800_B11","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: results of a phase II study.","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"key":"2019111713111289800_B12","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","article-title":"Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.","volume":"99","author":"Talpaz","year":"2002","journal-title":"Blood"},{"key":"2019111713111289800_B13","first-page":"2167","article-title":"Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.","volume":"8","author":"Kantarjian","year":"2002","journal-title":"Clin Cancer Res"},{"key":"2019111713111289800_B14","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"2019111713111289800_B15","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"key":"2019111713111289800_B16","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"2019111713111289800_B17","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.bloodjournal634789","article-title":"Prognostic discrimination in \u201cgood risk\u201d chronic granulocytic leukemia.","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"key":"2019111713111289800_B18","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon \u03b1.","volume":"90","author":"Hasford","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"2019111713111289800_B19","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1182\/blood.V82.2.398.398","article-title":"Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group.","volume":"82","author":"Hehlmann","year":"1993","journal-title":"Blood"},{"key":"2019111713111289800_B20","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/S0140-6736(95)92596-1","article-title":"UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response.","volume":"345","author":"Allan","year":"1995","journal-title":"Lancet"},{"key":"2019111713111289800_B21","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJM199403243301204","article-title":"Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia.","volume":"330","author":"Italian Cooperative Study Group on Chronic Myeloid Leukemia","year":"1994","journal-title":"N Engl J Med"},{"key":"2019111713111289800_B22","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood.V84.12.4064.bloodjournal84124064","article-title":"Randomized comparison of interferon alpha with busulfan and hydroxyurea in chronic myelogenous leukemia.","volume":"84","author":"Hehlmann","year":"1994","journal-title":"Blood"},{"key":"2019111713111289800_B23","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1200\/JCO.1999.17.6.1858","article-title":"Monitoring treatment and survival in chronic myeloid leukemia.","volume":"17","author":"Italian Cooperative Study Group on Chronic Myeloid Leukemia and Italian Group for Bone Marrow Transplantation","year":"1999","journal-title":"J Clin Oncol"},{"key":"2019111713111289800_B24","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1182\/blood.V98.10.3074","article-title":"Chronic myeloid leukemia and interferon \u03b1: a study of complete cytogenetic responders.","volume":"98","author":"Bonifazi","year":"2001","journal-title":"Blood"},{"key":"2019111713111289800_B25","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1056\/NEJM199707243370402","article-title":"Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia.","volume":"337","author":"Guilhot","year":"1997","journal-title":"N Engl J Med"},{"key":"2019111713111289800_B26","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1182\/blood.V99.5.1527","article-title":"A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia.","volume":"99","author":"Baccarani","year":"2002","journal-title":"Blood"},{"key":"2019111713111289800_B27","first-page":"256","article-title":"Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia.","volume":"88","author":"Rosti","year":"2003","journal-title":"Haematologica"},{"key":"2019111713111289800_B28","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1182\/blood-2004-03-0826","article-title":"Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia.","volume":"104","author":"Baccarani","year":"2004","journal-title":"Blood"},{"key":"2019111713111289800_B29","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2002-05-1451","article-title":"Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia.","volume":"101","author":"Kantarjian","year":"2003","journal-title":"Blood"},{"key":"2019111713111289800_B30","first-page":"2092","article-title":"The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment.","volume":"9","author":"Zonder","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2019111713111289800_B31","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/blood-2003-01-0025","article-title":"Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha.","volume":"102","author":"Cortes","year":"2003","journal-title":"Blood"},{"key":"2019111713111289800_B32","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1182\/blood-2003-11-3800","article-title":"High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.","volume":"103","author":"Kantarjian","year":"2004","journal-title":"Blood"},{"key":"2019111713111289800_B33","doi-asserted-by":"crossref","first-page":"2143a","DOI":"10.1182\/blood.V108.11.2143.2143","article-title":"High-dose (HD) imatinib provides better responses in patients with untreated early chronic phase (CP) CML [abstract].","volume":"108","author":"Aoki","year":"2006","journal-title":"Blood"},{"key":"2019111713111289800_B34","doi-asserted-by":"crossref","first-page":"2149a","DOI":"10.1182\/blood.V108.11.2149.2149","article-title":"Molecular responses in newly diagnosed chronic myelocytic leukemia (CML) patients treated with 800 mg imatinib daily: an update from the RIGHT Trial Study Group [abstract].","volume":"108","author":"Cortes","year":"2006","journal-title":"Blood"},{"key":"2019111713111289800_B35","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1182\/blood-2008-06-161737","article-title":"Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg\/day of imatinib as initial therapy.","volume":"112","author":"Hughes","year":"2008","journal-title":"Blood"},{"key":"2019111713111289800_B36","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"2019111713111289800_B37","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(02)07679-1","article-title":"BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study.","volume":"359","author":"Von Bubnoff","year":"2002","journal-title":"Lancet"},{"key":"2019111713111289800_B38","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"2019111713111289800_B39","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1182\/blood-2002-12-3659","article-title":"Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib.","volume":"101","author":"Corbin","year":"2003","journal-title":"Blood"},{"key":"2019111713111289800_B40","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance and the road to a cure of chronic myeloid leukemia.","volume":"110","author":"O'Hare","year":"2007","journal-title":"Blood"},{"key":"2019111713111289800_B41","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1200\/JCO.2004.03.050","article-title":"Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients.","volume":"22","author":"Peng","year":"2004","journal-title":"J Clin Oncol"},{"key":"2019111713111289800_B42","doi-asserted-by":"crossref","first-page":"429a","DOI":"10.1182\/blood.V108.11.429.429","article-title":"Correlation of pharmacokinetic data with cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib: an analysis of IRIS Study Data [abstract].","volume":"108","author":"Larson","year":"2006","journal-title":"Blood"},{"key":"2019111713111289800_B43","doi-asserted-by":"crossref","first-page":"1375a","DOI":"10.1182\/blood.V108.11.1375.1375","article-title":"Determination of imatinib plasma levels by high performance liquid chromatography (HPLC): evaluation of pharmacokinetic variability and haematological consequences [abstract].","volume":"108","author":"Haiat","year":"2006","journal-title":"Blood"},{"key":"2019111713111289800_B44","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Through imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia.","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"key":"2019111713111289800_B45","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u201creal-time\u201d quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia: a Europe Against Cancer program.","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"key":"2019111713111289800_B46","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/sj.leu.2402922","article-title":"Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.","volume":"17","author":"van der Velden","year":"2003","journal-title":"Leukemia"},{"key":"2019111713111289800_B47","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1038\/sj.leu.2401592","article-title":"Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia.","volume":"13","author":"van Dongen","year":"1999","journal-title":"Leukemia"},{"key":"2019111713111289800_B48","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"2019111713111289800_B49","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","article-title":"Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials.","volume":"112","author":"Branford","year":"2008","journal-title":"Blood"},{"key":"2019111713111289800_B50","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2307\/2530297","article-title":"One-sample multiple testing procedure for phase II clinical trials.","volume":"38","author":"Fleming","year":"1982","journal-title":"Biometrics"},{"key":"2019111713111289800_B51","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood-2001-12-0181","article-title":"A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.","volume":"100","author":"Ottmann","year":"2002","journal-title":"Blood"},{"key":"2019111713111289800_B52","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1182\/blood-2003-08-2958","article-title":"Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.","volume":"103","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"2019111713111289800_B53","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1182\/blood-2004-04-1389","article-title":"Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia.","volume":"104","author":"Towatari","year":"2004","journal-title":"Blood"},{"key":"2019111713111289800_B54","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.2005.03.2177","article-title":"High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group.","volume":"24","author":"Yanada","year":"2006","journal-title":"J Clin Oncol"},{"key":"2019111713111289800_B55","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1002\/cncr.22631","article-title":"Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).","volume":"109","author":"Ottmann","year":"2007","journal-title":"Cancer"},{"key":"2019111713111289800_B56","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/cncr.11223","article-title":"Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis.","volume":"97","author":"Kantarjian","year":"2003","journal-title":"Cancer"},{"key":"2019111713111289800_B57","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/shem.2003.50042","article-title":"The cytogenetic response as a surrogate marker of survival.","volume":"40","author":"Rosti","year":"2003","journal-title":"Semin Hematol"},{"key":"2019111713111289800_B58","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1038\/sj.leu.2402680","article-title":"Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.","volume":"16","author":"Merx","year":"2002","journal-title":"Leukemia"},{"key":"2019111713111289800_B59","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1046\/j.1365-2141.2003.04200.x","article-title":"The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia.","volume":"120","author":"Wang","year":"2003","journal-title":"Br J Haematol"},{"key":"2019111713111289800_B60","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1182\/blood-2005-11-4406","article-title":"BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML.","volume":"107","author":"Press","year":"2006","journal-title":"Blood"},{"key":"2019111713111289800_B61","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-04-2139","article-title":"Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.","volume":"11","author":"Cortes","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2019111713111289800_B62","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2005.03.2011","article-title":"Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.","volume":"24","author":"Iacobucci","year":"2006","journal-title":"J Clin Oncol"},{"key":"2019111713111289800_B63","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"2019111713111289800_B64","doi-asserted-by":"crossref","first-page":"185a","DOI":"10.1182\/blood.V112.11.185.185","article-title":"Cytogenetic and molecular response to imatinib in high risk (Sokal) chronic myeloid leukemia (CML): results of a European Leukemianet Prospective Study comparing 400 mg and 800 mg front-line [abstract].","volume":"112","author":"Baccarani","year":"2008","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/113\/15\/3428\/1483067\/zh801509003428.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/113\/15\/3428\/1483067\/zh801509003428.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T17:42:46Z","timestamp":1589564566000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/113\/15\/3428\/24930\/Results-of-highdose-imatinib-mesylate-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,9]]},"references-count":64,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2009,4,9]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2007-08-103499","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,9]]}}}